Novartis to launch new Zolgensma trial after FDA lifts restriction

Novartis (NOVN.S) will launch a new phase three study to expand the use of Zolgensma - the world's most expensive one time therapy at $2.1 million per patient treatment - after the U.S. regulator lifted its restrictions.